Skip Navigation
Toggle Menu
News & Events
Careers
Contact
About us
Background
History
Vision & Mission
Board of Directors
Suven Neuro
Locations
Business Segments
Drug Discovery & Development Support Services (DDDSS)
Synthetic and Medicinal Chemistry
Analytical Chemistry
In vitro Biology
ADME
Pharmacology
Toxicology
Bioanalysis
NCE Formulations
Drug Discovery & Research/Clinical pipeline
Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's
Masupirdine (SUVN-502) Cognitive deficits in AD
Samelisant (SUVN-G3031) Narcolepsy
Samelisant (SUVN-G3031) Cognitive Disorders
Ropanicant (SUVN-911) Depressive Disorders
Usmarapride (SUVN-D4010), Cognitive Disorders
SUVN-I6107, Cognitive Disorders and Schizophrenia
SUVN-M8036, Psychiatric Disorders
SUVN-D1044 Gastrointestinal Disorders
Clinical Pipeline
Research Pipeline
Investors
Financial Info
Quarterly Release
Annual Reports
Subsidiary Accounts
Pharma Results
Share Holder’s Info
Statutory Communications
Stock Information
AGM
EGM
Postal Ballot
Notice of Board Meeting
Un-paid Dividends
Scheme of Arrangement
Others
Rights Issue 2022
Corporate Info
Presentations
Advertisements
Credit Rating
MOA & AOA
Business Segments
Share Holder Contacts
Registrar & Share Transfer Agents (RTA)
Patent Updates
Corporate Governance
Committees of Board
Directors Familiarization program
Terms and conditions of appointment of ID’s
Policies
Code of Conduct
Sustainability
IMS Policy
Certifications & Awards
CSR Policies
CSR Gallery
BRSR Policies
Search
News & Events
2025
April 04, 2025
Suven Life Sciences to Make Oral and Poster Presentations Highlighting Clinical Development of Two Key Drug Candidates Samelisant and Masupirdine at American Academy of Neurology (AAN) 2025 Annual Meeting, San Diego, USA
View PDF
January 08, 2025
Suven Life Sciences Announces First Subjects Dosed in Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Positive Allosteric Modulator (M1 PAM) for the Treatment of Cognitive Disorders
View PDF
2024
October 03, 2024
Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA
View PDF
September 18, 2024
Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder (MDD)
View PDF
August 27, 2024
Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of “Study may proceed Letter” to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)
View PDF
July 29, 2024
Suven Life Sciences Announces Clinical and Preclinical Presentations at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia, USA
View PDF
June 03, 2024
Suven Life Sciences to Present New Data Analyses from Samelisant Phase-2 Study Results at the SLEEP 2024 Annual Meeting,Houston,USA
View PDF
May 29, 2024
Suven Life Sciences to Present Ropanicant Baseline data at 2024 American Society of Clinical ASCP Conference, Miami, USA
View PDF
April 15, 2024
Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Acade
View PDF
February 06, 2024
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropani
View PDF
January 30, 2024
BM Outcome 30.01.2024
View PDF
January 14, 2024
Clarification on Increase in Price
View PDF
January 03, 2024
Clarification on Increase in volume
View PDF
2023
October 30, 2023
Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant
View PDF
October 24, 2023
Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3
View PDF
July 17, 2023
Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.
View PDF
June 03, 2023
Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)
View PDF
June 01, 2023
Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA
View PDF
2022
November 29, 2022
Suven Presenting Study Design,Initiation of Phase-3 Global Clinical Trial of Masupirdine (SUVN-502)
View PDF
November 16, 2022
Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Tri
View PDF
November 11, 2022
Suven Life Sciences presenting Pre-clinical and Clinical data of NCEs at Neuroscience (SFN) 2022
View PDF
July 27, 2022
Suven Life sciences schedule Poster Presentation at AAIC -2022
View PDF
June 07, 2022
SLSL presenting key Scientific & Baseline Characteristic Data of Samelisant (SUVN-G3031) Phase-2
View PDF
April 01, 2022
Clarification on Increase in volume
View PDF
April 01, 2022
Clarification on Increase in volume
View PDF
March 17, 2022
Suven presents two scientific posters on Masupirdine at AD/PD 2022 - Advances in Science & Therapy
View PDF
March 16, 2022
Suven selected to be part of the scientific program at the American Academy of Neurology 2022
View PDF
2021
November 12, 2021
Suven Life Sciences presented several scientific posters at Neuroscience-2021 virtual conference
View PDF
November 08, 2021
Suven Life Sciences Ltd to present two Scientific posters on Masupirdine at 2021 Clinical Trials
View PDF
October 11, 2021
Clarification on Price Movement
View PDF
August 16, 2021
Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist
View PDF
July 26, 2021
Suven Life Sciences Ltd to present key Scientific Data at the Alzheimer’s Association International
View PDF
June 10, 2021
SLEEP-2021 Virtual meeting - Suven e-poster presentations
View PDF
2020
December 28, 2020
Clarification on Price Movement
View PDF
December 28, 2020
Clarification on Price Movement
View PDF
December 28, 2020
Clarification on Price Movement
View PDF
August 27, 2020
S L S announces five poster presentations including Phase-2 POC study design for SUVN-G3031
View PDF
June 26, 2020
Clarification on Price Movement
View PDF
April 27, 2020
Intimation of Fire Incidence at Jeedimetla unit in Hyderabad
View PDF
April 06, 2020
Suven Life Sciences presented exploratory sub-group analyses data from Masupirdine (SUVN-502) Phase
View PDF
February 11, 2020
Q3 & 9M FY20 Schedule of conference call for Investors
View PDF
2019
December 19, 2019
SUVEN receives EIR from US FDA for its Pashamylaram facility
View PDF
December 06, 2019
Masupirdine (SUVN-502) Oral presentation at CTAD 2019 on 4 th December at San Diego
View PDF
November 30, 2019
Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients
View PDF
November 11, 2019
Q2 & H1 FY20 Schedule of conference call for Investors
View PDF
September 24, 2019
First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the
View PDF
August 07, 2019
Q1 FY20 Schedule of conference call for Investors
View PDF
July 09, 2019
Suven Life Sciences announces the delay in topline phase 2 study data of masupirdine (SUVN-502)
View PDF
May 23, 2019
Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of Masup
View PDF
May 22, 2019
Q4 and FY19 Schedule of conference call for Investors
View PDF
April 22, 2019
Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner,
View PDF
April 13, 2019
Suven receives court approval of “Stalking Horse” Agreement to buy the assets of Rising Pharmaceutic
View PDF
April 03, 2019
Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri Lanka
View PDF
March 29, 2019
Suven Life Sciences secures Product Patents in Eurasia, Europe, South Korea and Sri Lanka
View PDF
March 08, 2019
Suven announces the asset purchase agreement of Rising Pharmaceuticals through its joint venture par
View PDF
February 05, 2019
Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December’ 2018
View PDF
February 05, 2019
Suven outcome of the Board Meeting
View PDF
January 16, 2019
Suven Life Sciences secures Product Patents in Australia and Singapore
View PDF
Archives